Resumo
Definição
História e exame físico
Principais fatores diagnósticos
- presença de fatores de risco
- crescimento da lesão ao longo de semanas a meses
- pápula arredondada, saliente
- pequenos pontos pretos na superfície da lesão
Outros fatores diagnósticos
- lesões satélites
- lesões nos dedos ou nas dobras ungueais
- lesões faciais
- fissuras
- hiperceratose
- coloração branca-acinzentada ou marrom claro
- pápula filiforme com espículas pontiagudas
Fatores de risco
- imersão em água
- profissões que envolvem o manuseio de carne ou peixe
- roer unhas
- idade abaixo de 35 anos
- imunocomprometido
Investigações diagnósticas
Primeiras investigações a serem solicitadas
- nenhum exame inicial
Investigações a serem consideradas
- biópsia de pele
- coloração com imunoperoxidase
- cultura da pele
Algoritmo de tratamento
verruga comum: imunocompetente
verruga comum: imunocomprometido
verruga filiforme
Colaboradores
Autores
Angela Yen Moore, MD
Director
Arlington Center of Dermatology
Primary Investigator
Arlington Research Center
Arlington
Clinical Assistant Professor
Baylor University Medical Center
Dallas
Clinical Assistant Professor
University of Texas Medical Branch
Galveston
TX
Declarações
Dr. Moore receives funds as an advisory board member (A), consultant (C), clinical study investigator (I), and speaker (SP) – for Abbvie (I,SP), Almirall (C,I,SP), Arcutis (I), Biofrontera (C,I), Boehringer Ingelheim (I), Bristol-Myers Squibb (C,I), Dermavant (I), DS Biopharma (I), Eli Lilly (I), EpiHealth (A), Evolus (A), Galderma (I), Incyte (I), Janssen (I), Leo (A,SP), Mayne Pharma (C,I), Nimbus (I), Novartis (I), Parexel (I), Pfizer (I,SP), UCB (I), Verrica (I), Vyne (I,SP).
Agradecimentos
Dr Angela Yen Moore would like to gratefully acknowledge Dr Leonid Izikson, the previous contributor to this topic. LI declares that he has no competing interests.
Revisores
Brenda L. Pellicane, MD
Dermatologist
Wayne State University School of Medicine
Department of Dermatology
Detroit
MI
Declarações
BLP declares that she has no competing interests.
David Cassarino, MD, PhD
Assistant Professor
Department of Pathology and Laboratory Medicine
University of California
Los Angeles
CA
Disclosures
DC declares that he has no competing interests.
Jashin J. Wu, MD
Chief Dermatology Resident
University of California
Irvine
CA
Disclosures
JJW declares that he has no competing interests.
Sam Gibbs, FRCP
Consultant Dermatologist
Dermatology Department
The Great Western Hospital
Swindon
UK
Disclosures
SG declares that he has no competing interests.
References
Key articles
Gibbs S, Harvey I, Sterling J, et al. Local treatments for cutaneous warts: systematic review. BMJ. 2002;325:461.Full text Abstract
Kwok CS, Gibbs S, Bennett C, et al. Topical treatments for cutaneous warts. Cochrane Database Syst Rev. 2012;(9):CD001781.Full text Abstract
Dall'oglio F, D'Amico V, Nasca MR, et al. Treatment of cutaneous warts: an evidence-based review. Am J Clin Dermatol. 2012;13:73-96. Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Verrugas planas
- Verrugas palmoplantares
- Ceratose seborreica
More DifferentialsGuidelines
- Guidelines for the prevention and treatment of opportunistic infections in children with and exposed to HIV
- Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV
More GuidelinesPatient information
Verrugas (comuns)
Vacina contra o HPV (papilomavírus humano)
More Patient information
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer